The FDA has granted Axonics Modulation Technologies approval for full-body MRI use for the 129 participants of a pivotal trial of its sacral neuromodulation device. The trial is designed to evaluate use of the device in treating overactive bladder.
FDA OKs full-body MRI use in Axonics' SNM device trial
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.